ArticlePloS one2022
Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023.Frontiers in neuroscience · 2024Pooled it
- Elevated BrainAGE precedes cognitive impairment and improves prediction of future cognitive decline.medRxiv : the preprint server for health sciences · 2026Article
- Predicting the progression of MCI and Alzheimer's disease on structural brain integrity and other features with machine learning.GeroScience · 2026Article
- The Synergy of Artificial Intelligence and 3D Bioprinting: Unlocking New Frontiers in Precision and Tissue Fabrication.Advanced functional materials · 2025Article
- Predicting future cognitive impairment in preclinical Alzheimer's disease using multimodal imaging: a multisite machine learning study.medRxiv : the preprint server for health sciences · 2025Article
- Multi-Modal Deep Clustering Survival Machines for Alzheimer's Disease Subtype Discovery.... IEEE International Conference on Computer Vision workshops. IEEE International Conference on Computer Vision · 2025Article
- Knockout: A simple way to handle missing inputs.Transactions on machine learning research · 2025Article
- Neurotechnological Approaches to Cognitive Rehabilitation in Mild Cognitive Impairment: A Systematic Review of Neuromodulation, EEG, Virtual Reality, and Emerging AI Applications.Brain sciences · 2025Review
- Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- AlzheimerViT: harnessing lightweight vision transformer architecture for proactive Alzheimer's screening.Frontiers in medicine · 2025Article
- Disintegration at the Syntax-Semantics Interface in Prodromal Alzheimer's Disease: New Evidence from Complex Sentence Anaphora in Amnestic Mild Cognitive Impairment (aMCI).Journal of neurolinguistics · 2024Article
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.Alzheimer's research & therapy · 2024Article
- Multimodal Alzheimer's disease classification through ensemble deep random vector functional link neural network.PeerJ. Computer science · 2024Article
- A Framework for Interpretability in Machine Learning for Medical Imaging.IEEE access : practical innovations, open solutions · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative condition that progresses over decades. Early detection of individuals at high risk of future progression toward AD is likely to be of critical significance for the successful treatment and/or prevention of this devastating disease. In this paper, we present an empirical study to characterize how predictable an individual subjects' future AD trajectory is, several years in advance, based on rich multi-modal data, and using modern deep learning methods. Crucially, the machine learning strategy we propose can handle different future time horizons and can be trained with heterogeneous data that exhibit missingness and non-uniform follow-up visit times. Our experiments demonstrate that our strategy yields predictions that are more accurate than a model trained on a single time horizon (e.g. 3 years), which is common practice in prior literature. We also provide a comparison between linear and nonlinear models, verifying the well-established insight that the latter can offer a boost in performance. Our results also confirm that predicting future decline for cognitively normal (CN) individuals is more challenging than for individuals with mild cognitive impairment (MCI). Intriguingly, however, we discover that prediction accuracy decreases with increasing time horizon for CN subjects, but the trend is in the opposite direction for MCI subjects. Additionally, we quantify the contribution of different data types in prediction, which yields novel insights into the utility of different biomarkers. We find that molecular biomarkers are not as helpful for CN individuals as they are for MCI individuals, whereas magnetic resonance imaging biomarkers (hippocampus volume, specifically) offer a significant boost in prediction accuracy for CN individuals. Finally, we show how our model's prediction reveals the evolution of individual-level progression risk over a five-year time horizon. Our code is available at https://github.com/batuhankmkaraman/mlbasedad.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.